SCHEMBL4843918

SCHEMBL4843918

CCc1nc(/C=C\c2cn(-c3ccccc3)nc2OCc2ccc(OCc3nc(-c4ccco4)oc3C)c(OC)c2)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.39
TSHR P16473 4/20 0.39
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 3/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
LMNA P02545 4/20 0.33
USP2 O75604 3/20 0.33
ALOX15 P16050 2/20 0.33
MAPK1 P28482 2/20 0.33
TP53 P04637 1/20 0.33
SIRT1 Q96EB6 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
PPARA Q07869 4/20 0.32
F2RL3 Q96RI0 2/20 0.32
RECQL P46063 1/20 0.31
ADORA3 P0DMS8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843920 1.00 PPARG (0.44) PPARGSMN1; SMN2TSHRKDM4EHSD17B10
SCHEMBL4846836 1.00 PPARG (0.44) PPARGSMN1; SMN2TSHRKDM4EHSD17B10
SCHEMBL4854458 0.93 PPARG (0.45) PPARGSMN1; SMN2TSHRKDM4EHSD17B10
SCHEMBL4846855 0.93 PPARG (0.45) PPARGSMN1; SMN2TSHRKDM4EHSD17B10
SCHEMBL4846864 0.93 PPARG (0.45) PPARGSMN1; SMN2TSHRKDM4EHSD17B10
SCHEMBL4853947 0.90 PPARG (0.36) PPARGSMN1; SMN2TSHRKDM4EMAPT
SCHEMBL4853927 0.90 PPARG (0.36) PPARGSMN1; SMN2TSHRKDM4EMAPT
SCHEMBL4845603 0.90 PPARG (0.45) PPARGSMN1; SMN2TSHRKDM4EHSD17B10
SCHEMBL4843957 0.90 PPARG (0.45) PPARGSMN1; SMN2TSHRKDM4EHSD17B10
SCHEMBL4843967 0.90 PPARG (0.45) PPARGSMN1; SMN2TSHRKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PPARG 536/4885SMN1; SMN2 4339/4885TSHR 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.